Brief: Longboard Pharmaceuticals Completes Enrollment Of Phase 1B/2A Pacific Study Evaluating Lp352 For The Treatment Of Developmental And Epileptic Encephalopathies
23/08/2023 13:30
Aug 23 (Reuters) -
* LONGBOARD PHARMACEUTICALS COMPLETES ENROLLMENT OF PHASE
1B/2A
PACIFIC STUDY EVALUATING LP352 FOR THE TREATMENT OF
DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES
* LONGBOARD PHARMACEUTICALS INC - PACIFIC TOPLINE RESULTS
REMAIN
ON TRACK FOR AROUND YEAR-END 2023
Source text for Eikon: ID:nBw65CwQGa
Further company coverage: LBPH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions